Compared to current drugs used for palliative treatment of MG, that display lower affinity and selectivity for AChE, short PK (t1/2 < 30 min) and short residence time (except for carbamates that form transient covalent adducts with AChE), binding kinetics and PK/PD of C-547 make this compound as a promising leader drug for improving sustained treatment of MG and related diseases. Here, ACHE is linked to myasthenia gravis.